These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 33224862)
1. An affordable immunohistochemical approach to estimate the prevalence of Choden S; Keelawat S; Jung CK; Bychkov A Gland Surg; 2020 Oct; 9(5):1867-1877. PubMed ID: 33224862 [TBL] [Abstract][Full Text] [Related]
2. VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting Choden S; Keelawat S; Jung CK; Bychkov A Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32150939 [TBL] [Abstract][Full Text] [Related]
3. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218 [TBL] [Abstract][Full Text] [Related]
4. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846 [TBL] [Abstract][Full Text] [Related]
7. VE1 immunohistochemistry is an adjunct tool for detection of BRAF Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405 [TBL] [Abstract][Full Text] [Related]
8. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153 [TBL] [Abstract][Full Text] [Related]
9. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma. Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810 [TBL] [Abstract][Full Text] [Related]
11. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis. Parker KG; White MG; Cipriani NA Head Neck Pathol; 2020 Dec; 14(4):1067-1079. PubMed ID: 32358715 [TBL] [Abstract][Full Text] [Related]
14. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825 [TBL] [Abstract][Full Text] [Related]
16. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Zagzag J; Pollack A; Dultz L; Dhar S; Ogilvie JB; Heller KS; Deng FM; Patel KN Surgery; 2013 Dec; 154(6):1199-204; discussion 1204-5. PubMed ID: 23931769 [TBL] [Abstract][Full Text] [Related]
17. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry cannot replace DNA analysis for evaluation of Szymonek M; Kowalik A; Kopczyński J; Gąsior-Perczak D; Pałyga I; Walczyk A; Gadawska-Juszczyk K; Płusa A; Mężyk R; Chrapek M; Góźdź S; Kowalska A Oncotarget; 2017 Sep; 8(43):74897-74909. PubMed ID: 29088832 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues. Zhang Y; Liu L; Liu Y; Cao N; Wang L; Xing C Medicine (Baltimore); 2021 Apr; 100(16):e25566. PubMed ID: 33879712 [TBL] [Abstract][Full Text] [Related]
20. Association Between BRAF Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]